TRANSCEND FL at ASH 2023
TRANSCEND FL: Lisocabtagene Maraleucel as Second-Line Therapy for Patients With High-Risk R/R Follicular Lymphoma

Released: December 13, 2023

Activity

Progress
1
Course Completed